Spironolactone and hair loss in women: what the studies really say

Hair carries real weight as a marker of identity and femininity. When the parting starts to widen, the crown thins, and the scalp shows through, the psychological toll can be enormous. Women dealing with androgenetic alopecia already know this: tracking down an effective treatment often feels like chasing your tail.

Which is why a particular drug keeps coming up in dermatology consultations: spironolactone. It was originally developed for hypertension, but it happens to have anti-androgenic properties that caught the attention of hair loss specialists more than twenty years ago. So how well does it actually work? And who stands to benefit?

Why women’s hair falls out: the little-known role of hormones

There’s a widespread assumption that baldness is a man’s problem. It isn’t. The same hormonal processes that destroy hair follicles in men exist in women too, they just show up differently.

The main offender is DHT (dihydrotestosterone), a hormone derived from testosterone. In women who are genetically predisposed, DHT latches onto androgen receptors in the hair follicles and gradually miniaturises them. Hairs become finer and shorter with each cycle, until eventually they stop growing altogether.

This is textbook androgenetic alopecia, following the progression described by the Ludwig scale: thinning at the crown, a broadening parting, and a scalp that becomes increasingly visible.

What’s particularly maddening is that this can happen even when blood tests show perfectly normal hormone levels. The issue isn’t necessarily excess testosterone, it’s how sensitive the follicle receptors are. The hair cycle gets disrupted, the growth phase shortens, the hair thins, and nothing on a blood panel flags it up.

Small wonder, then, that so many women feel at a loss sitting across from their dermatologist.

Spironolactone: how it works on hair

Spironolactone was never designed with baldness in mind. It’s an anti-aldosterone diuretic that’s been prescribed for decades to manage hypertension and fluid retention. But dermatologists noticed something unexpected: the molecule blocks androgen activity.

In practice, it works on two levels. It stops DHT from binding to androgen receptors in the hair follicle, and it dials down androgen production from the adrenal glands. The upshot is that follicular miniaturisation slows, or in some cases halts entirely. Where things go well, partial regrowth becomes a realistic prospect.

This anti-androgenic property has long been put to use in treating hirsutism and hormonal acne (Rathnayake & Sinclair, 2010). Applying it to hair loss was a logical extension, much like finasteride, which also tackles the hormonal pathway but through a different mechanism (5-alpha reductase inhibition).

Important note: Spironolactone is never prescribed to men for hair loss. The risk of gynaecomastia and feminising effects rules it out entirely. This is a treatment reserved exclusively for women.

The numbers: how effective is it really?

Online opinions on spironolactone for hair are all over the place, and honestly, that’s not surprising. Results vary hugely between individuals. The clinical data, though, gives us something more solid to work with.

The key reference is a 2023 meta-analysis published in Cureus, pooling data from 413 patients across multiple studies (Aleissa et al., 2023). The headline figure: 56.6% of treated women saw a noticeable improvement in their hair.

Combine spironolactone with minoxidil, and the number rises to 65.8%. On its own, spironolactone sits closer to 43%.

A UCLA study looking at 166 women pushed things further: 3 out of 4 patients experienced either stabilisation or improvement on spironolactone (Famenini et al., 2015). One interesting finding: women who also had hirsutism or acne responded even more strongly. That makes sense when you think about it, since those symptoms point to more pronounced androgenic activity.

In 2025, a randomised, double-blind trial confirmed this trend: spironolactone at 100 mg daily, paired with topical minoxidil, produced an average gain of 9.5 terminal hairs per cm² at the vertex, versus 5.3 in the placebo group (Wattanachanya et al., 2025). On an area as exposed as the crown, that’s a meaningful difference.

A word of caution, though: this takes time. And that’s precisely where a lot of women give up. Every study points the same way: results at 12 months are markedly better than those seen at 6 months (Aleissa et al., 2023). In the early months, the main effect is slowing hair loss. Visible regrowth typically doesn’t appear until somewhere between month six and month twelve. Pulling the plug early because nothing seems to be happening is one of the most common mistakes.

Dosage and side effects: what to expect

The right dose

Studies have tested dosages anywhere from 25 to 200 mg daily, but the general consensus puts the effective range at 100 to 200 mg (Wang et al., 2023). Below 100 mg, the impact on hair tends to be minimal.

The typical approach: begin at 50 mg, then step up gradually. For women who struggle with higher doses, there’s another route worth knowing about. Sinclair et al. (2017) trialled a very low-dose combination, just 25 mg of spironolactone with 0.25 mg of oral minoxidil, in 100 patients. The outcome: an improvement of 1.3 points on the Sinclair scale over 12 months, alongside a meaningful drop in daily hair shedding. Less dramatic, certainly, but much better tolerated.

Side effects, without the scaremongering

On the whole, spironolactone is well tolerated. The 2023 meta-analysis (Aleissa et al.) breaks it down:

• Scalp itching: around 19% of patients
• Menstrual irregularities (spotting, cycle changes): around 12%
• Facial hypertrichosis (a touch ironic when you’re treating hair loss): around 7%
• Stopping treatment because of side effects: just 2.8%

Serious complications like hypotension or hyperkalaemia crop up in fewer than 2% of women. Regular check-ups are still advisable, particularly in the first few months.

The 2025 trial adds a bit more nuance: at 100 mg, roughly one in three patients reported menstrual irregularities (Wattanachanya et al., 2025). This is worth raising with your gynaecologist, especially if you’re of childbearing age.

One point that can’t be glossed over: spironolactone is strictly contraindicated in pregnancy. The risk of feminising a male foetus means reliable contraception is essential throughout treatment.

Spironolactone and minoxidil: the winning combination?

Do you have to choose one or the other? Not necessarily. Minoxidil and spironolactone work through completely different mechanisms. Minoxidil boosts blood flow to the follicle to stimulate regrowth directly. Spironolactone tackles the hormonal root by blocking DHT.

The two complement each other well, and the data backs this up: close to two out of three women improve with the combination, compared with fewer than one in two on spironolactone alone.

For women whose hair loss has a clear hormonal dimension, whether that’s polycystic ovary syndrome, postmenopausal thinning, acne, or hirsutism, spironolactone brings something to the table that minoxidil on its own simply cannot.

There’s also a topical option. A 1% spironolactone gel has demonstrated results on a par with 5% topical minoxidil, with fewer systemic side effects (Sayed et al., 2025). Worth considering if oral medication isn’t something you’re keen on.

When spironolactone is no longer enough

Let’s be straightforward: spironolactone isn’t a cure-all. Roughly 4 out of 10 women don’t see a satisfactory response from the drug alone. How well it works depends on the stage of hair loss, how long it’s been going on, and each woman’s individual hormonal profile.

The critical thing to understand is that spironolactone can slow shedding and improve the density of existing hair, but it won’t bring back follicles that have already disappeared. Once the scalp is clearly visible through the hair, medication alone won’t restore the volume that’s been lost. That’s a reality worth facing squarely.

Which is why other options exist, and they’re well worth exploring depending on your circumstances. Hair medicine now offers non-surgical treatments like PRP (platelet-rich plasma) injections, low-level laser therapy, and Regenera Activa mesografting, a technique that uses your own stem cells to stimulate cellular regeneration.

For women with established, longer-standing alopecia, hair transplant in Turkey remains the definitive answer. The DHI (Direct Hair Implantation) technique suits women particularly well: grafts are placed between existing hairs without shaving the recipient area, giving a discreet, natural-looking result.

Dr. Emrah Cinik brings over 20 years’ experience and more than 50,000 procedures to this field, with protocols developed specifically for female pattern baldness. His approach frequently combines transplantation with complementary treatments such as PRP (Platelet-Rich Plasma), which is included in all packages.

For a concrete sense of what’s achievable, the before/after gallery is well worth a look.

The key takeaway? Don’t wait. Whether the route is spironolactone, minoxidil, hair restoration therapies, or transplantation, earlier intervention consistently delivers better outcomes. A free consultation lets us assess your situation and put together a plan that works for you.

Scientific references

Aleissa, M., Alkhodair, R., Albasri, K., & Aljohani, S. (2023). The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. Cureus, 15(8), e43559. https://pmc.ncbi.nlm.nih.gov/articles/PMC10502763/

Famenini, S., Slaught, C., Duan, L., & Goh, C. (2015). Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. Journal of the American Academy of Dermatology, 73(4), 705-706. https://pmc.ncbi.nlm.nih.gov/articles/PMC4573453/

Rathnayake, D., & Sinclair, R. (2010). Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatologic Clinics, 28(3), 611-618. https://pubmed.ncbi.nlm.nih.gov/20510769/

Sayed, K. S., et al. (2025). Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment of Female Pattern Hair Loss. Journal of Clinical and Aesthetic Dermatology. https://pmc.ncbi.nlm.nih.gov/articles/PMC12251981/

Sinclair, R. D., Dawber, R., & Baraniuk, J. (2017). Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. International Journal of Dermatology, 57(1), 104-109. https://pubmed.ncbi.nlm.nih.gov/29231239/

Wang, C. H., Gao, Y., Zhu, L. J., & Xu, W. R. (2023). The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review. Clinical, Cosmetic and Investigational Dermatology, 16, 603-612. https://pmc.ncbi.nlm.nih.gov/articles/PMC10010138/

Wattanachanya, L., et al. (2025). Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot study. International Journal of Women’s Dermatology, 11(3), e227. https://pmc.ncbi.nlm.nih.gov/articles/PMC12448166/